AIDSVAX immunization induces HIV-specific CD8+T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection
AIDSVAX immunization induces HIV-specific CD8+T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection
复制标题
DOI：
10.1016/j.vaccine.2008.11.071
复制
发表时间：
2009-02-11
期刊：
影响因子：
5.5
通讯作者：
Cao, Huyen
中科院分区：
文献类型：
--
作者：
Jones, Norman G.;DeCamp, Allan;Cao, Huyen
HIV疫苗的免疫保护的相关性仍然不确定。在美国和欧洲进行的第一个HIV疫苗有效性试验VAX 004旨在评估rgp 120包膜亚基（AIDSVAX B/B，VaxGen）是否可以诱导部分或完全保护免受HIV-1感染。在减少感染或HIV感染后血浆病毒血症水平方面没有效果。我们在接受疫苗的志愿者中发现了疫苗特异性CD 8 + T细胞的证据，无论行为风险如何。令人惊讶的是，CD 8反应在继续感染艾滋病毒的参与者中显着更高。这些结果表明，AIDSVAX免疫接种可能会增强预先存在的免疫反应-由于感染前的暴露。疫苗诱导的免疫谱可以作为HIV易感性的生物学标记。(C)2008爱思唯尔有限公司保留所有权利。
Correlates of immune protection from HIV vaccines remain undefined. The first HIV vaccine efficacy trial in the US and Europe VAX004, was designed to assess whether rgp120 envelope subunits (AIDSVAX B/B, VaxGen) can induce Partial or complete protection from HIV-1 infection. No effectiveness in the reduction of either the acquisition of infection or levels of plasma viremia after HIV infection was noted. We found evidence of vaccine-specific CD8+ T cells in volunteers who received the vaccine, regardless of behavioral risk. Surprisingly, the CD8-response is significantly higher in participants who would go on to contract HIV infection. These results suggest that AIDSVAX immunization may boost preexisting immune responses-due to pre-infection exposure. and a vaccine-induced immune profile may serve as a biological marker for HIV susceptibility. (C) 2008 Elsevier Ltd. All rights reserved.